13125 Berlin, de
+49 (30) 941084-138
Eckert & Ziegler delivers a record result
The strong euro had an adverse effect on foreign currency sales and sales growth in all segments, costing the Group EUR 4.4 million in sales compared to the previous year. On a currency-adjusted basis, sales would have increased by EUR 34.5 million or 25%. Organic, real sales growth, i.e. sales adjusted for currency effects and acquisitions and disposals made in 2017 and 2018, amounted to EUR 25.6 million or 18%.
The Isotope Products segment posted the largest increase in sales based on continuing operations, increasing its sales by EUR 22.6 million or 25% to EUR 112.3 million due to the consolidation of the Gamma-Service Group acquired at the end of May 2017 and the strong demand in the energy sector.
Sales in the Radiation Therapy segment increased by EUR 4.7 million or 18% to EUR 30.6 million, driven by solid sales generated by HDR tumour irradiation systems and WOMED acquired in January 2018.
The Radiopharma segment increased sales by 18% to EUR 31.5 million, mainly driven by pharmaceutical radioisotopes.
Cash and cash equivalents as at 31 December 2018 amounted to EUR 54.2 million. While this represents a decline of EUR 3.5 million compared to the end of 2017 it is mainly due to the purchase of own shares in 2018. Without these expenses cash and cash equivalents would have been EUR 10 million higher. However, this is still a very solid result, which together with the lack of bank debt makes the Eckert & Ziegler Group optimally prepared to tackle future projects.
In the 2019 financial year, the Group expects sales and EBIT to increase to around EUR 180 million and EUR 23.5 million, respectively This should result in a consolidated net income of around EUR 18 million, translating into earnings per share of EUR 3.50. The forecasts assume an exchange rate not moving above USD 1.20 per EUR.
The Executive Board and the Supervisory Board will propose a dividend of EUR 1.20 per dividend-bearing share (previous year: EUR 0.80) to the Annual General Meeting to be held on 29 May 2019.
The complete financial statements for the 2018 financial year can be viewed here: https://www.ezag.com/home/investors/reports/
The use of information published here for personal information and editorial processing is generally free of charge. Please clarify any copyright issues with the stated publisher before further use. In the event of publication, please send a specimen copy to firstname.lastname@example.org.